The Dystrophic Epidermolysis bullosa clinical pipeline comprises 20+ notable therapeutic agents in different stages of clinical development varying from Gene therapies, Cell therapies, RNA‐targeting therapy, Protein therapies, Topical therapies, and Small molecules.

 

DelveInsight’s ‘Dystrophic Epidermolysis Bullosa (DEB) Pipeline Insights’ report presents a complete picture of the available therapies, Dystrophic Epidermolysis Bullosa emerging therapies in different phases of clinical development, key companies working in the Dystrophic Epidermolysis Bullosa pipeline domain, and future potential of the space.

 

Some of the focal points picked from the Dystrophic Epidermolysis Bullosa Pipeline report:

• Exhaustive analysis of the Dystrophic Epidermolysis Bullosa Pipeline demonstrates opportunities and scope in the future with the involvement of 20+ key players and 20+ key therapies.
• Key Dystrophic Epidermolysis Bullosa pipeline candidates such as genetically corrected cultured epidermal autograft, INM-755, B-VEC, FCX-007, AGLE-102, PTR-01, FCX-007, and others are under investigation in different phases of clinical trials for the treatment of Dystrophic Epidermolysis Bullosa.
• The entry of novel therapeutics is expected to boost the Dystrophic Epidermolysis Bullosa treatment market in the coming years.
• DelveInsight estimates that late-stage products such as EB-101, FCX-007, and B-VEC will have a major impact on the Dystrophic Epidermolysis Bullosa treatment market.
• Key prominent pharma players including Holostem Terapie Avanzate, InMed Pharmaceuticals, Krystal biotech, Castle Creek Biosciences, Zikani Therapeutics, Aegle Therapeutics, Phoenix Tissue Repair, among others are actively involved in strengthening the Dystrophic Epidermolysis Bullosa pipeline portfolio.
• EB-101 (Abeona Therapeutics) is an autologous, gene-corrected cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer from severe epidermal wounds that impact the length and quality of their lives. The therapy is currently in the phase 3 stage of development to treat Dystrophic Epidermolysis Bullosa.

 

Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight

 

The Dystrophic Epidermolysis Bullosa Pipeline reports offer a holistic scenario of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Dystrophic Epidermolysis Bullosa domain.

 

Dystrophic Epidermolysis Bullosa: Overview

Epidermolysis Bullosa (EB) is a group of inherited disorders that causes blistering, which in several cases can be life-threatening to newborns and infants. It predominantly affects the skin and mucous membrane. A subtype of Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa (DEB) is characterized by the site of blister formation in the lamina densa within the basement membrane zone and the upper dermis.

 

Dystrophic Epidermolysis Bullosa Pipeline Drugs

Drug	Company	Phase	MoA	RoA
RGN-137	RegeneRx Biopharmaceuticals	Phase II	Angiogenesis inducing agents; Apoptosis inhibitors; Cell movement activators; Collagen stimulants	Topical
B-VEC	Krystal biotech	Phase III	Gene transference	Topical
FCX-007	Castle Creek Biosciences	Phase III	Cell replacements; Collagen type VII replacements	Intradermal
Research programme- Ribosomal modulators	Zikani Therapeutics	Preclinical	Ribosomal RNA modulators	NA
AGLE-102	Aegle Therapeutics	Phase I/II	Collagen type VII replacements	Topical
PTR-01	Phoenix Tissue Repair	Phase II	Collagen type VII replacements	Intravenous
TXA127	Constant Therapeutics	Preclinical	Proto-oncogene protein c-mas-1 agonists	Intravenous

 

Request for Sample to know more @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight

 

Dystrophic Epidermolysis Bullosa Therapeutics Assessment

The Dystrophic Epidermolysis Bullosa Pipeline report presents a kaleidoscopic view of the DEB emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

• Mono

By Stage

• Discovery
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Molecule Type

• Cell therapy
• Peptides
• Small interfering RNA
• Small molecule
• Gene therapy

By Route of Administration

• Oral
• Intradermal
• Intravenous
• Topical

By Mechanism of Action

• Collagen type VII replacements
• Gene Transference
• RNA interference
• Cannabinoid receptor agonists
• Ribosomal RNA modulators

By Targets

• Cannabinoid receptor
• Caspase 1
• Interleukin 1 beta
• Serine Protease targeted therapy

 

 

Table of Contents

1	Report Introduction
2	Executive Summary
3	Dystrophic Epidermolysis Bullosa Disease Overview
4	DEB Pipeline Therapeutics Comparative Analysis
5	Dystrophic Epidermolysis Bullosa Therapeutic Assessment
6	Dystrophic Epidermolysis Bullosa – DelveInsight’s Analytical Perspective
7	In-depth Commercial Dystrophic Epidermolysis Bullosa Assessment
8	Dystrophic Epidermolysis Bullosa Collaboration Deals
9	Late Stage Dystrophic Epidermolysis Bullosa Products (Phase III)
10	Mid-Stage Dystrophic Epidermolysis Bullosa Products (Phase II)
11	Early Stage Dystrophic Epidermolysis Bullosa Products (Phase I)
12	Pre-clinical and Discovery Stage DEB Products
13	Inactive Dystrophic Epidermolysis Bullosa Pipeline Products
14	Key Dystrophic Epidermolysis Bullosa Products
15	Unmet Needs
16	DEB Market Drivers and Barriers
17	Future Perspectives and Conclusion
18	Analyst Views
19	Key Dystrophic Epidermolysis Bullosa Companies
20	Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight